Hemophilia is an X-linked blood coagulation genetic disorder, which can cause significant disability. Replacement therapy for coagulation factor VIII (hemophilia A) or factor IX (hemophilia B) may result in the development of high-affinity alloantibodies ('inhibitors') to the replacement therapy, thus making it ineffective. Therefore, there is interest in directing immunological responses towards tolerance to infused factors.
INTRODUCTION
Hemophilia is an X-linked monogenic blood coagulation disorder with significant morbidity, affecting primarily men [1] . Mutations in F8 and F9 genes lead to development of hemophilia A and B, respectively, of which hemophilia A is more prevalent (1 : 5000 male births) [2, 3] . Severity of hemophilia is based on residual activity of coagulation factors, where levels of less than 1% are classified as severe, 1-5% moderate, and 5-40% mild [4] . Factor replacement has been used for therapy and prophylaxis since the 1950s. An increasing number of plasma-derived and recombinant FVIII and FIX products are available or in clinical development.
Development of inhibitory antibodies (inhibitors) is a major complication of replacement therapy, making it ineffective [5] . Inhibitors are highaffinity alloantibodies directed against infused clotting factors, and are more common in hemophilia A patients [6] . Less than 5% of patients with severe hemophilia B develop inhibitors, mostly those with large F9 gene deletions [7] . Inhibitors are usually observed in previously untreated patients (PUP) within 50 days of exposure to factor product [6, 8] . Bypassing agents are used to treat bleeding episodes, but the only way to eradicate inhibitors is through immune tolerance induction (ITI). The mechanism of inhibitor formation is complex and not completely understood. Immune responses are initiated when antigen-presenting cells (APCs) encounter the 'unfamiliar' replacement factor molecule and present it via HLA class II, marking it for elimination. Co-stimulatory signals via cell surface molecules such as cluster of differentiation 40 (CD40), or CD80/86 (which are found in dendritic cells and required for T-cell survival), or ICOS ('inducible co-stimulator'), and secretion of proinflammatory cytokines are required for T-cell activation [9] . CD4 þ T-helper cells enable B-cell activation and differentiation into memory B cells or antibody-producing plasma cells, which neutralize the infused clotting factor [10] (Fig. 1). surgical intervention. Factor products have a relatively short half-life and require frequent administration [11] [12] [13] . One approach to increase systemic retention of clotting factors is pegylation. Pegylated factor products (Adynovate, Rebinyn) require less frequent administration than plasma-derived or recombinant products [14] . IgG1 Fc-conjugated clotting factor (Eloctate, Alprolix) can also prolong half life by binding to the neonatal Fc receptor (FcRn) and delaying lysosomal degradation [15] [16] [17] . There are also reports that Fc fusion products may be more tolerogenic, as suggested by preclinical studies and when used in ITI in a pediatric patient [18, 19] . Although the mechanism of tolerance by Fc-conjugated clotting factor is not completely understood, it has been suggested that upon degradation, the Fc portion is processed and presented by APCs via MHC II, which promotes induction of regulatory T cells (Tregs) [20] . Fc fusion proteins also offer the ability for transplacental delivery of FVIII antigen, which can be exploited for perinatal tolerance induction. Transfer of maternal IgG to the fetal circulation is mediated by transcytosis upon
KEY POINTS
Formation of inhibitory antibodies against coagulation factors is a major problem in the treatment of hemophilia.
Diverse and innovative approaches to tolerance induction have emerged in recent years.
Gene therapies are being developed that can simultaneously achieve correction of hemophilia and immune tolerance.
Immunomodulatory drugs and oral tolerance may accomplish prophylactic tolerance induction.
Tolerogenic lymphocyte therapies, for example, using engineered regulatory T cells, hold promise. 
INHIBITOR FORMATION AND ERADICATION: CURRENT TOLERANCE INDUCTION PROTOCOLS
To date, the only clinically proven method to eradicate inhibitors and induce antigen-specific tolerance to infused FVIII or FIX is ITI [26] . During ITI, patients receive daily, high dose (up to 200 IU/kg/ day) infusions of clotting factors [27, 28] . One of the working mechanistic theories of ITI is that repetitive, high doses of antigen can suppress activated T-cell responses by overstimulation with antigen, followed by anergy and deletion [29] , and has also been suggested to induce Tregs [10, 30] . High antigen doses also eliminate antigen-specific memory B cells, as was demonstrated in hemophilia A mice [5, 31, 32] . Outcome of ITI is variable: it is successful in 60-70% of hemophilia A patients but only 30% of hemophilia B patients [5, 33] . ITI in patients with FIX inhibitors often has to be discontinued because of severe allergic reactions to FIX or development of nephrotic syndrome [7, [34] [35] [36] . The mechanism leading to nephrotic syndrome is poorly understood. This complication typically occurs 8-9 months into high-dose ITI in patients with previous allergic phenotype, and likely reflects an immunotoxicity. Even in patients with successful outcome of ITI, inhibitors can reappear once they are re-exposed to regular factor infusions when antigen-specific T and memory B cells become reactivated [37, 38] . This review will explore new approaches of treating hemophilia through developing novel tolerance induction protocols.
IMMUNE MODULATORY DRUGS
An obvious approach to reduce inhibitor formation is the use of immune suppressive drugs, similar to their use for autoimmune diseases or in organ or cell transplantation. However, more desirable than general immune suppression is a targeted intervention promoting immune tolerance. Various approaches, including transient blockage of different pathways that promote co-stimulation to CD4 þ T cells, have been successfully employed in hemophilic mice [39] .
Conceptually, shifting the balance of the T-cell response from an effector to a Treg phenotype should induce immune tolerance (Fig. 2) . In this regard, the mTOR inhibitor rapamycin is ideally suitable, as antigen presentation in the presence of rapamycin causes programmed cell death of conventional CD4 þ T cells, whereas CD4
þ Treg are induced and expanded. Differential use of signaling pathways and metabolic requirements account for the ability of Treg to survive in the presence of rapamycin [40] . A 1-month regimen of FVIII and rapamycin tolerized hemophilia A mice to FVIII without compromising immune competence [41] . Unless peptide antigens are used, representing CD4 þ T-cell epitopes, FVIII or FIX protein antigen dose during the regimen is a critical parameter. The effect of rapamycin can be enhanced through combination with other drugs, for example, to manipulate dendritic cells in a manner that augments Treg induction [40, 42, 43] . In an alternative method, co-administration of FVIII and rapamycin-containing nanoparticles that are based on biodegradable polymers (polylactic-co-glycolic acid, PLGA) prevented and reversed inhibitors in hemophilia A mice [44 & ,45] . Interestingly, the antigen (peptide or protein) does not have to be co-packaged with rapamycin into the nanoparticles.
Direct targeting of B cells to eliminate anti-FVIII formation has been tested in humans in a Phase II clinical study. However, the B-cell depleting monoclonal anti-CD20 (Rituximab) showed only a modest effect in reducing existing inhibitors and preventing anamnesis after repeated exposure. [46] . One limitation may be that antibody-producing plasma cells do not express CD20 and are therefore not targeted. Addition of a specific toleranceinducing step may also be necessary to prevent inhibitor relapse. A recent study in hemophilia A mice found that anti-CD20 and rapamycin can be combined for more effective reversal of inhibitors [47 & ]. This approach was superior to using either drug alone or the combination of rapamycin and Treg therapy.
TOLERANCE INDUCTION VIA GENE THERAPY
Gene therapy with adeno-associated viral (AAV) vectors has resulted in sustained correction of monogenic disorders in multiple recent gene therapy trials. The first Food and Drug Administration (FDA)-approved gene therapy drug for a genetic disease (Luxturna), to correct an inherited form of blindness, is based on an AAV vector [48, 49] . AAV is a small, nonpathogenic, nonintegrating, replication deficient parvovirus with vast tissue tropism. It has a packaging capacity $5 kb, and can transduce nondividing cells in vivo [50] . The liver is an ideal target for gene delivery for hemophilia A and B. Both FVIII and FIX are synthetized and secreted by the liver; FIX is produced by hepatocytes whereas FVIII is primarily made in endothelial cells [51 ,54-57] . Follow-up in both long-term and a recent trial by Spark Therapeutics demonstrated sustained expression of near-normal FIX activity after gene transfer [48,53 & ]. By using the hyperactive FIX-Padua variant, it was possible to use a vector dose 5-10-fold lower compared with previous trials without compromising therapy [ . Experimental approaches to promote tolerance to clotting factor therapy that may serve to replace or supplement conventional immune tolerance induction. In-vivo gene transfer into the tolerogenic liver microenvironment using either adenoassociated viral or lentiviral vectors promoted tolerance in several preclinical models. The immunomodulatory drug rapamycin, either alone or encapsulated in nanoparticles, is tolerogenic when co-administered with antigen. Fc-conjugation of FVIII/FIX may not only increase half-life in circulation but also facilitate tolerance induction. Oral administration of lettuce-encapsulated clotting factor leads to tolerance, which is mediated by the induction of at least two types of Tregs. Cellular therapy with either ex-vivo expanded Tregs, engineered Tregs expressing specific TCRs, or CAR-Tregs that have receptor specificity to clotting factor without MHC restriction, have all been shown to promote tolerance in animal models of hemophilia.
occurs in hepatocytes from a cell type-specific promoter.
Importantly, the liver represents a tolerogenic site of gene expression, as it is constantly exposed to foreign proteins from the gut and circulation [59] . Immune tolerance to FVIII and FIX induced by hepatic gene transfer depends on induction and expansion of antigen-specific
Tregs, which actively suppress antibody and T-cell responses [60, 61] . At the same time, activationinduced cell death is required to induce tolerance [61] . Thus, tolerance is maintained upon subsequent intravenous delivery of factor product or secondary gene transfer [62] [63] [64] . Multiple studies in hemophilic dogs demonstrate that hepatic AAV gene transfer suppresses inhibitor formation and can even eradicate preexisting inhibitors [65] [66] [67] . This was also successful and well tolerated in hemophilia B mice with preexisting IgE/anaphylactic reactions against FIX [63] . Tregs were found to be critical for both induction and maintenance of tolerance. Tolerance can also be achieved by hepatic gene transfer using lentiviral vectors with optimized regulation of gene expression using microRNA targets that eliminate expression in certain APCs and/or cell typespecific promoters [ 
TOLEROGENIC CELL THERAPIES
Dramatic advances have been made in recent years in cancer immunotherapy using gene-modified lymphocytes. Similar concepts may apply to tolerance induction in hemophilia [72] . For example, primary B cells can be engineered to induce tolerance to FVIII or FIX [73] [74] [75] . However, production of vectors that efficiently transduce human B cells remains a limitation. Alternatively, engineering of Treg is an emerging and promising concept [76, 77 && ]. Substantial progress has been made with ex-vivo expansion of human Treg, and gene transfer technologies for their engineering are available and approved for clinical use [78] [79] [80] [81] . In hemophilic mice, transplant of autologous ex-vivo expanded Treg promoted tolerance induction to FVIII and FIX, likely by reducing the ability of dendritic cells to provide co-stimulation and by promoting induction of endogenous Treg [82] . Nonetheless, an antigen-specific approach, requiring fewer Treg for transplant, would be more desirable. Antigen specificity of Tregs can be re-directed to FVIII by transducing them with T-cell receptors (TCR) specific for a FVIII MHC II-peptide complex. Tregs expressing an HLA-DRA DRB1Ã0101-restricted T-cell epitope specific to the C2 protein of FVIII were indeed shown to suppress antibody formation against FVIII in vivo upon transplant into 'humanized' hemophilia A mice [83] . Utilizing chimeric artificial receptors (CARs) would eliminate MHC restrictions and therefore, the need to customize the receptor for individual patients. In a first proof-of-principle study, a single-chain variable fragment (scFv) of a FVIII-A2 domain epitope immunoglobulin was isolated from a phage library and linked to second-generation intracellular signal transduction domains to direct a response to FVIII upon gene transfer to human CD4
lo Treg. Effectiveness of this approach was demonstrated in hemophilia A mice [77 && ] (Fig. 2) . In-vitro studies suggest that these CAR-Treg still require APCs for stimulation although they do not rely on recognition of peptide-MHC complexes [77 && ]. As these studies on engineered FVIII-specific Treg utilized human cells transplanted into mice for in-vivo evaluation, durability of this approach awaits further study, as does evaluation in preimmune animals compared with prevention of inhibitor formation.
ORAL TOLERANCE
Perhaps more readily acceptable as a prophylactic regimen to prevent inhibitor formation in previously untreated patients (PUPs) could be to induce systemic immune tolerance for hemophilia A and B by delivering the antigen orally [84, 85] . This concept relies on the ability of the gut to control unwanted responses to food antigens through a complex immune regulatory mechanism [86] [87] [88] . A growing body of evidence now supports the usefulness of oral tolerance to combat food allergies [89, 90] . Transgenic plant cells producing high amounts of clotting factor in chloroplasts ('transplastomic' plants) provides low production costs and bioencapsulation via the plant cell wall [91] . Commensal bacteria in the gut are able to degrade cell wall components, thus releasing the antigen. Expression of a FVIII or FIX fusion protein that includes a transmucosal carrier such as CTB (cholera toxin B subunit) assures effective delivery across the gut epithelium [92] .
This concept was successfully employed to prevent inhibitor formation and anaphylaxis against FIX in hemophilia B mice using initially tobacco, and subsequently lettuce plants [93, 94] , upon repeated oral delivery (two times per week for 2 months) over a wide dose range. Intact antigen could be stored for at least 2 years in the form of powder of freeze-dried plant cells. Production of clinical grade material was efficient and could be Tolerance induction in hemophilia Sherman et al.
scaled-up in a hydroponic system [94] . Repeated oral delivery to hemophilia B dogs suppressed antibody formation against FIX, so that correction of coagulation was consistently achieved upon weekly IV delivery of human FIX over an 8-week period [95 & ]. Experiments in mice also showed the ability to reverse the pathogenic antibody response against FIX [87] . Mechanistic studies showed increases in subsets of dendritic cells in the immune system of the small intestine that are known to promote Treg induction, antigen-specific up-regulation of immune-suppressive cytokines in response, and induction of CD4 þ Tregs that actively suppressed antibody formation upon adoptive transfer [87] . Oral delivery of combination of either heavy chain and C2 or heavy chain and light chain antigens (derived from B domain deleted, BDD, FVIII) suppressed inhibitor formation against FVIII in different strains of hemophilia A mice, again at low-antigen doses [96, 97] .
CONCLUSION
In conclusion, a number of recent innovative and diverse approaches have been developed to induce immune tolerance to coagulation factors. These include fusion proteins, oral tolerance, immune modulatory drugs, in-vivo gene therapies, cell therapies, among others. Until now, no clinical prophylactic immune tolerance protocol exists to prevent inhibitor formation in PUPs, which may change with the emergence of these new technologies, pending further studies and risk-benefit analysis. Complexity and costs also vary substantially for these diverse approaches, representing additional factors that may affect feasibility for routine clinical use.
Conflicts of interest R.W.H. is member of the scientific advisory board of AGCT (Applied Genetic Technologies Corporation) and has received royalty payments from Spark Therapeutics as well as grant support from Novo Nordisk and Bayer in the past. 
REFERENCES AND RECOMMENDED READING

